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Cerebral venous thrombosis after vaccination against 
COVID-19 in the UK: a multicentre cohort study
Richard J Perry, Arina Tamborska, Bhagteshwar Singh, Brian Craven, Richard Marigold, Peter Arthur-Farraj, Jing Ming Yeo, Liqun Zhang, 
Ghaniah Hassan-Smith, Matthew Jones, Christopher Hutchcroft, Esther Hobson, Dana Warcel, Daniel White, Phillip Ferdinand, Alastair Webb, 
Tom Solomon, Marie Scully, David J Werring*, Christine Roffe*, on behalf of the CVT After Immunisation Against COVID-19 (CAIAC) collaborators†
Summary
Background A new syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a 
rare side-effect of vaccination against COVID-19. Cerebral venous thrombosis is the most common manifestation of 
this syndrome but, to our knowledge, has not previously been described in detail. We aimed to document the features 
of post-vaccination cerebral venous thrombosis with and without VITT and to assess whether VITT is associated with 
poorer outcomes.
Methods For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination 
preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of 
cerebral venous thrombosis symptoms, or blood test results. We collected clinical characteristics, laboratory results 
(including the results of tests for anti-platelet factor 4 antibodies where available), and radiological features at hospital 
admission of patients with cerebral venous thrombosis after vaccination against COVID-19, with no exclusion criteria. We 
defined cerebral venous thrombosis cases as VITT-associated if the lowest platelet count recorded during admission was 
below 150 × 10⁹ per L and, if the D-dimer was measured, the highest value recorded was greater than 2000 μg/L. We 
compared the VITT and non-VITT groups for the proportion of patients who had died or were dependent on others to 
help them with their activities of daily living (modified Rankin score 3–6) at the end of hospital admission (the primary 
outcome of the study). The VITT group were also compared with a large cohort of patients with cerebral venous thrombosis 
described in the International Study on Cerebral Vein and Dural Sinus Thrombosis.
Findings Between April 1 and May 20, 2021, we received data on 99 patients from collaborators in 43 hospitals across 
the UK. Four patients were excluded because they did not have definitive evidence of cerebral venous thrombosis on 
imaging. Of the remaining 95 patients, 70 had VITT and 25 did not. The median age of the VITT group (47 years, 
IQR 32–55) was lower than in the non-VITT group (57 years; 41–62; p=0·0045). Patients with VITT-associated cerebral 
venous thrombosis had more intracranial veins thrombosed (median three, IQR 2–4) than non-VITT patients 
(two, 2–3; p=0·041) and more frequently had extracranial thrombosis (31 [44%] of 70 patients) compared with non-
VITT patients (one [4%] of 25 patients; p=0·0003). The primary outcome of death or dependency occurred more 
frequently in patients with VITT-associated cerebral venous thrombosis (33 [47%] of 70 patients) compared with the 
non-VITT control group (four [16%] of 25 patients; p=0·0061). This adverse outcome was less frequent in patients 
with VITT who received non-heparin anticoagulants (18 [36%] of 50 patients) compared with those who did not 
(15 [75%] of 20 patients; p=0·0031), and in those who received intravenous immunoglobulin (22 [40%] of 55 patients) 
compared with those who did not (11 [73%] of 15 patients; p=0·022).
Interpretation Cerebral venous thrombosis is more severe in the context of VITT. Non-heparin anticoagulants and 
immunoglobulin treatment might improve outcomes of VITT-associated cerebral venous thrombosis. Since existing 
criteria excluded some patients with otherwise typical VITT-associated cerebral venous thrombosis, we propose new 
diagnostic criteria that are more appropriate.
Funding None.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Introduction
Globally, more than 4·1 million people have died 
from COVID-19.1 In response to this public health 
emergency, several vaccines against COVID-19 have been 
developed, with more than 3·7 billion doses administered 
worldwide.2 After the introduction of the adenovirus 
vector vaccine ChAdOx1 (Oxford–AstraZeneca), five cases 
of severe venous thrombosis with thrombocytopenia 
were reported in Norway, each starting 7–10 days after 
administration of the first vaccine dose. Four of these 
cases had cerebral venous sinus thrombosis.3 This 
syndrome has since been termed vaccine-induced 
immune thrombotic thrombocytopenia (VITT).3–5 A 
similar condition has been described with another 
adenovirus vector vaccine, Ad26.COV2.S (Johnson & 
Johnson).6,7 There are also case reports in which two 
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mRNA vaccines, mRNA-1273 (Moderna)8,9 and BNT162b2 
(Pfizer–BioNTech),10 are associated with thrombocy-
topenia, although typically with purpura and mucosal 
bleeding8–11 rather than thrombosis.11
Scully and colleagues4 proposed the following definition 
for VITT: patients presenting with acute thrombosis 
and thrombocytopenia with elevated D-dimers, using a 
D-dimer threshold of <2000 μg/L for VITT unlikely 
and >4000 μg/L for VITT suspected. They showed that 
22 (96%) of 23 patients with VITT had antibodies against 
platelet factor 4 (PF4). Similar observations were made 
in other smaller case series.3,5
We aimed to document the clinical features, laboratory 
and imaging results, and outcomes in a large cohort 
of patients with VITT-associated cerebral venous 
thrombosis, and to compare these with patients with 
cerebral venous thrombosis without VITT, and with 
historical data from the 624 patients in the International 
Study on Cerebral Vein and Dural Sinus Thrombosis 
(ISCVT) cohort.12
Methods
Study design and participants
For this multicentre cohort study, clinicians involved in 
the care of patients with cerebral venous thrombosis after 
vaccination against COVID-19 were identified through 
existing networks of communication among UK doctors, 
advertisement through the Association of British 
Research in context
Evidence before this study
We searched PubMed on May 26, 2021, for articles published 
in any language in 2021, with titles containing any of the 
following three search terms or their synonyms: “thrombosis”, 
“platelet”, or “PF4”, together with any of the following: 
“ChAdOx”, “AstraZeneca”, “Vaxzevria”, “Ad26.COV2.S”, 
“Janssen”, “Johnson”, “mRNA-1273”, “Moderna”, “BNT162b2”, 
“Pfizer”, “Comirnaty”, “COVID” and “vaccine”, or “SARS” and 
“vaccine”. 63 articles were identified, of which 29 were case 
reports or small case series (nine focused specifically on cerebral 
venous sinus thrombosis), six were summaries of drug side-
effect reports submitted to surveillance agencies, six were 
consensus statements regarding guidelines for diagnosis or 
management, 19 were reviews, commentaries, or editorials, 
and three were relevant immunological studies in individuals 
who were vaccinated and remained healthy. Most case reports 
and small series were of vaccine-induced immune thrombotic 
thrombocytopenia (VITT) after vaccination with the adenovirus 
vector vaccine ChAdOx1 (Oxford–AstraZeneca), with the typical 
features of very low platelets, very high D-dimers, and, 
most commonly, cerebral venous sinus thrombosis or hepatic 
portal vein thrombosis. A similar syndrome has been reported 
following another adenovirus vector vaccine Ad26.COV2.S 
(Janssen/Johnson & Johnson). In both cases, anti-platelet 
factor 4 antibodies were found in most patients. The mRNA-
based vaccines produced by Moderna (mRNA-1273) and Pfizer–
BioNTech (BNT162b2) have also been associated with a 
syndrome of profound thrombocytopenia, but in this case the 
phenotype is typically idiopathic thrombocytopenic purpura, 
with a purpuric rash and mucosal bleeding as the most typical 
features. Although there have been occasional reports of 
thrombosis after mRNA vaccines, these did not have the 
characteristics of VITT and could have been incidental. 
Although cerebral venous thrombosis is the most severe 
manifestation of VITT, to date, to our knowledge, there have 
been no large studies focusing on this condition, and none of 
the reports so far have included a control group, making it 
difficult to draw inferences about how this condition differs 
from cerebral venous thrombosis without VITT.
Added value of this study
To our knowledge, our report describes the largest study of 
cerebral venous thrombosis after vaccination against 
COVID-19. We can make the first direct comparison between 
70 patients with VITT-associated cerebral venous thrombosis 
and 25 patients who developed cerebral venous thrombosis 
after vaccination but did not have VITT, in addition to 
secondary comparisons with a large historical cohort with 
cerebral venous thrombosis. Our results show, for the first 
time to our knowledge, that when they are compared with 
those without VITT, patients with VITT-associated cerebral 
venous thrombosis were younger, had fewer venous 
thrombosis risk factors, and were more likely to have been 
given the ChAdOx1 vaccine. They developed more extensive 
cerebral venous thrombosis with more veins or sinuses 
thrombosed, and multiple intracerebral haemorrhage was 
more common. They were more likely to have concurrent 
extracranial venous or arterial thromboses. Their outcomes at 
the end of hospital admission were worse, with higher rates 
of death and disability. Although the response of patients 
with VITT-associated cerebral venous thrombosis to 
treatment is difficult to assess in a purely observational study, 
non-heparin anticoagulants and intravenous 
immunoglobulin were both associated with better outcomes. 
The starting criteria for VITT, based on low platelets and high 
D-dimers, appeared to miss two patients who had typical 
features for this condition.
Implications of all the available evidence
VITT is specifically associated with adenovirus vector vaccines 
against COVID-19 and urgent work is needed to elucidate the 
trigger for this reaction, in the hope that future vaccines can be 
designed to avoid this. Clinicians need to be aware of the 
clinical, laboratory, and radiological markers of this condition, 
as without prompt treatment the outcome is very poor. 
Adoption of our proposed definition of VITT-associated cerebral 
venous thrombosis should make it less likely that atypical cases 
will be missed, but these diagnostic criteria will need to be 
tested as more data accumulate.
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Neurologists and the British Association of Stroke 
Physicians, and via reports submitted to the UK 
Medicines and Healthcare products Regulatory Agency 
(MHRA). Clinicians were asked to submit all cases in 
which COVID-19 vaccination preceded the onset of 
cerebral venous sinus thrombosis or cortical vein 
thrombosis, regardless of the type of vaccine, interval 
between vaccine and onset of cerebral venous thrombosis 
symptoms, or blood test results. There were no exclusion 
criteria for the study. Clinicians were encouraged to 
report their cases to the MHRA, the UK Expert 
Haematology Panel, and Public Health England, so data 
from those sources will include most of our cases. The 
study includes a combination of retrospective and 
prospective cases.
Data were extracted from clinical notes, discharge 
summaries, results systems, and radiology reports, by 
consultants (56 patients), specialist trainees (29 patients), 
other clinicians involved in patient care (four patients), or 
trained stroke research practitioners (six patients). We 
included details of exposure to COVID-19 vaccines in 
patients with cerebral venous thrombosis, for a case-
control comparison between those with and without VITT. 
We collected baseline data on demographics, venous 
thrombosis risk factors (including cerebral venous 
thrombosis risk factors identified in ISCVT12), clinical 
features, laboratory results, radiological findings, and 
treatments given, with death or dependency (modified 
Rankin score13 3–6) at the end of hospital admission as the 
primary outcome. Data were checked centrally for 
omissions, duplications, or inconsistencies, and data 
queries were sent back to the submitting clinicians until 
these were resolved. Case report forms were received 
between April 1 and May 20, 2021. The UK Health Research 
Authority confirmed that this surveillance study, using 
routine patient data in anonymised form, could proceed 
without the need for patient consent or review by an ethics 
committee.
Defining VITT-associated cerebral venous thrombosis 
We defined cerebral venous thrombosis cases as VITT-
associated if the lowest platelet count recorded during 
admission was below 150 × 10⁹ per L and, if the D-dimer 
was measured, the highest value recorded was greater 
than 2000 μg/L, the lower of the two thresholds 
suggested by Scully and colleagues.4 These criteria are 
referred to as the starting criteria (different from the 
proposed criteria in the panel). Before proceeding with 
any comparisons between groups, we examined the 
frequency distributions of the minimum platelet count 
and maximum D-dimers recorded during admission 
across the whole study population, to confirm the appro-
priateness of these diagnostic thresholds in a population 
of patients with cerebral venous thrombosis.
We then compared the characteristics of patients with 
VITT-associated cerebral venous thrombosis with the 
patients in our study who did not satisfy our starting 
criteria for VITT. The VITT group was also compared 
with the historical ISCVT cohort.12
Anti-PF4 antibody assays
Anti-PF4 antibody tests used were as follows: automated 
chemiluminescent heparin-induced thrombocytopenia 
assay (HemosIL Acustar HIT-IgG assay; Instrumentation 
Laboratory; Milan, Italy), ELISA (Asserachrom 
HPIA-IgG; Diagnostica Stago; Reading, UK; Lifecodes 
PF4 IgG; Immucor; Norcross, GA, USA; and Zymutest 
HIA IgG; Hyphen Biomed; Neuville-sur-Oise, France), 
flow cytometry platelet activation assay (HITAlert; 
Diapharma Group; West Chester Township, OH, USA), 
or gel agglutination assay (Diamed ID-PaGIA Heparin/
PF4 Antibody Test; Bio-Rad Laboratories; Hercules, CA, 
USA).
Statistical analysis
We compared categorical variables between groups using 
χ² tests, unless the expected number of patients in any one 
category was less than five, in which case Fisher’s exact 
test was used. The age distribution of VITT-associated 
Panel: Diagnostic criteria for VITT-associated cerebral venous thrombosis
Definite VITT-associated cerebral venous thrombosis
• Post-vaccine cerebral venous thrombosis (proven on neuroimaging and with first 
symptom of venous thrombosis within 28 days of vaccination against COVID-19)
and
• Thrombocytopenia (lowest recorded platelet count <150 × 10⁹ per L or documented 
platelet count decrease to less than 50% of baseline) 
and
• Anti-PF4 antibodies (detected on ELISA or functional assay)
Probable VITT-associated cerebral venous thrombosis
• Post-vaccine cerebral venous thrombosis
and
• Either thrombocytopenia or anti-PF4 antibodies
and
• Coagulopathy (D-dimer >2000 μg/L or fibrinogen <2·0 g/L with no other explanation 
such as severe sepsis, malignancy, or recent trauma or surgery) or extracranial venous 
thrombosis (clinical or imaging evidence with onset since vaccination against 
COVID-19)
Possible VITT-associated cerebral venous thrombosis
• Post-vaccine cerebral venous thrombosis
and
• Either thrombocytopenia or anti-PF4 antibodies
In assessing the interval since vaccination, the date of the first symptom of venous 
thrombosis should be used, even if this was a symptom of an extracranial thrombosis. 
The retrospective time window within which a pre-cerebral venous thrombosis baseline 
platelet count can be used to define a fall of greater than 50% has not been defined, 
as this will depend on what medical events have occurred in the interim.
PF4=platelet factor 4. VITT=vaccine-induced immune thrombotic thrombocytopenia.
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cerebral venous thrombosis was compared with a single 
value representing the median age of patients in the 
ISCVT cohort,12 using the one-sample Wilcoxon signed 
rank test. All other continuous variables were compared 
using the Mann-Whitney U test.
The frequency of cases submitted was calculated for 
each 5-year interval between the ages of 15 years and 
70 years. The frequency was then corrected for the 
number of patients vaccinated in each age group, using a 
bin width of 10 years to match with national data from 
OpenSAFELY.14
Statistical analysis was done using Microsoft Excel for 
Microsoft 365 MSO with the Real Statistics Resource 
Pack plugin.
Role of the funding source 
There was no funding source for this study.
Results
Between April 1 and May 20, 2021, we received data on 
99 patients from collaborators in 43 hospitals across the 
UK. Four patients were excluded because they did not 
have definitive evidence of cerebral venous thrombosis 
on imaging (appendix p 9). In 83 (87%) of 95 patients, the 
modality on which cerebral venous thrombosis was 
shown was CT venography (figure 1). The lowest platelet 
count during admission was available for all 95 patients 
and the highest D-dimer was available in 62 (89%) of 
70 patients with VITT and 20 (80%) of 25 patients without 
VITT.
76 (80%) of 95 patients were investigated for anti-PF4 
antibodies on one or more anti-PF4 antibody tests. 
74 patients were tested with at least one ELISA. 17 of these 
patients were additionally tested with an automated 
chemiluminescent HIT assay (Acustar HIT-IgG assay), of 
whom nine patients were positive on ELISA but negative 
on Acustar. No patients were positive on Acustar and 
negative on ELISA (appendix p 2). Six patients were tested 
on a flow cytometry platelet activation assay (Diapharma 
HITAlert assay) and one patient on a gel agglutination 
assay (Diamed ID-PaGIA Heparin/PF4 Antibody test). 
Patients were counted as anti-PF4 positive if the result by 
any method was positive.
We examined the study population for evidence from 
their platelet counts and D-dimer results that there 
might be two subgroups, postulated to be those with 
VITT and those without VITT. Given existing evidence 
that anti-PF4 antibodies are a reliable diagnostic marker 
for VITT,3–5 we also classified patients by anti-PF4 status, 
as follows: positive on any test, negative in all tests used 
always including at least one ELISA test, or not tested. 
We found evidence to support the hypothesis that there 
was a distinct subgroup of patients with platelet counts 
below 150 × 10⁹ per L who, when tested, tended to be 
positive for anti-PF4 antibodies, as predicted for the VITT 
group (figure 2A). However, one patient with evidence 
of anti-PF4 antibodies on two ELISA assays (Stago 
Asserachrom and Immucor Lifecodes) had a lowest 
platelet count of 158 × 10⁹ per L (patient B; appendix p 3).
Among the 75 patients found to be thrombocytopenic 
on their lowest platelet count, seven were negative 
for anti-PF4 antibodies on ELISA tests. Two of these 
patients satisfied the starting criteria for VITT, with 
thrombocytopenia and peak D-dimers greater than 
2000 μg/L but were negative on two different ELISA 
assays (Stago Asserachrom and Hyphen Zymutest; 
patients E and F; appendix p 3).
We plotted a histogram for the highest D-dimer on a 
logarithmic scale (figure 2B). The distribution was 
bimodal. The value separating the two empty bars near 
the centre of the chart, the lower of which is 
labelled 1585, was log10(D-dimer) 3·3, equivalent to 
D-dimer of 1995 μg/L. Therefore, this distribution 
supports the incorporation of a D-dimer threshold 
of 2000 μg/L into the criteria for diagnosing VITT-
associated cerebral venous thrombosis.
The median time interval between vaccination and 
cerebral venous thrombosis symptom onset was 9 days 
(IQR 7–12) in patients with VITT and 11 days (6–21) in 
those without VITT (table 1; appendix p 10). One patient 
with VITT developed clumsiness of the left arm 40 days 
after the first and only dose of ChAdOx1 vaccine, the first 
manifestation of a cortical vein thrombosis. However, the 
patient had developed a deep vein thrombosis, their first 
Figure 1: Imaging from patient A, who had typical vaccine-induced immune thrombotic thrombocytopenia-
associated cerebral venous thrombosis
This man in his 50s was well before vaccination with the ChAdOx1 (AstraZeneca) vaccine, but 17 days later 
developed a headache, abdominal pain, vomiting, dysphasia and confusion. (A) Axial CT without contrast showing 
a large haemorrhagic venous infarct in the left temporal lobe. (B–E). Axial CT venogram. Arrows indicate voids left 
by thrombus in the left transverse sinus (B, C) and the left sigmoid sinus (D) and lack of opacification of the left 
internal jugular vein (E). Each structure can be compared with its well-opacified counterpart on the right side. 
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manifestation of VITT, 21 days after vaccination. The deep 
vein thrombosis was initially treated with tinzaparin, but 
the patient was found to be thrombocytopenic before this 
treatment was started. This patient was the only individual 
in the whole study to receive any form of heparin within 
the 2 weeks preceding the cerebral venous thrombosis.
The age distribution of patients with VITT-associated 
cerebral venous thrombosis showed an abrupt increase 
in the frequency of cases in patients older than 45 years, 
in keeping with the UK COVID-19 vaccination strategy 
(appendix p 10). The patients in this study were all 
vaccinated on or before April 30, 2021, and before this 
date most individuals vaccinated in the UK were aged 
45 years or older (appendix p 1). When adjusted for the 
UK rate of vaccination per age group, using data from 
OpenSAFELY,14 the step-change in frequency above age 
45 years was no longer apparent (appendix p 10).
We compared the 70 patients with VITT-associated 
cerebral venous thrombosis with the 25 patients who 
developed cerebral venous thrombosis without evidence 
of VITT after vaccination, as well as with historical data 
from the 624 patients with cerebral venous thrombosis 
in the ISCVT cohort (table 1).12 Patients with VITT were 
significantly younger than patients who did not have 
VITT (table 1). All 70 cases of VITT-associated cerebral 
venous thrombosis occurred after a first dose of the 
ChAdOx1 (Oxford–AstraZeneca) vaccine, compared 
with 21 (85%) of 25 patients with non-VITT cerebral 
venous thrombosis, in whom the remaining four 
patients had been given their first dose (three patients) 
or second dose (one patient) of BNT162b2 (Pfizer–
BioNTech) vaccine. The clinical features of cerebral 
venous thrombosis were similar in the VITT and 
non-VITT groups (appendix p 4).
Figure 2: Distributions of lowest platelet counts (A) and highest D-dimers (B) recorded during admission, in patients with anti-PF4 antibodies, without 
PF4 antibodies, or not tested
The x-axis labels represent the lowest limit of the bin, so that the label 100 refers to the range 100–125, the label 126 refers to the range 126–157 and so on. Patients 
with atypical anti-PF4 results are described in the appendix (p 3) as follows: the patient with a normal platelet count and positive anti-PF4 antibodies is patient B; 
the patient with normal D-dimers and positive anti-PF4 antibodies is patient C; the two patients with high D-dimers and negative anti-PF4 antibodies are patients E 
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Patients with VITT-associated cerebral venous 
thrombosis had lower levels of fibrinogen at hospital 
admission than the non-VITT group (table 1; appendix 
p 11), although both medians were within the normal 
range (1·9–4·3 g/L). 56 (97%) of 58 patients with VITT 
who were investigated for anti-PF4 antibodies using an 
ELISA assay tested positive; the characteristics of the other 
two patients are given in the appendix (p 3; patients E 
and F). Two patients with anti-PF4 antibodies on ELISA 
were classified as non-VITT using the current criteria, one 
because her platelet count never fell below 150 × 10⁹ per L 
(patient B) and the other because her D-dimers never rose 
above 2000 μg/L (patient C, appendix p 3).
The number of veins thrombosed on the first venogram 
was higher in the VITT group (median 3, IQR 2–4) than 
in the non-VITT group (2, 2–3; p=0·041; appendix pp 5, 11). 
On neuroimaging at the time of admission, patients with 
VITT were more likely to have evidence of multiple 
venous infarction (10 [14%] of 70 patients) than those 
without VITT (0 of 25 patients; p=0·046), and more likely 
to have multiple intracerebral haemorrhages (23 [33%] of 
70 patients) than non-VITT patients (three [12%] of 
25 patients; p=0·045; appendix p 5).
31 (44%) of 70 patients with VITT-associated cerebral 
venous thrombosis had evidence of extracranial venous 
thrombosis, arterial thrombosis, or both, with pulmonary 
embolism and hepatic portal vein thrombosis being 
particularly common (appendix p 5). By contrast, 
extracranial thrombosis was only seen in one (4%) of 
25 patients classified as non-VITT. This patient 
(patient D; appendix p 3) had pulmonary embolism and 
hepatic vein thrombosis in addition to cerebral venous 
thrombosis and presented with a platelet count of 
57 × 10⁹ per L. Even though the patient was not classified 
as having VITT in this study, because her highest 
D-dimer was only 822 μg/L, the clinical team treated her 
for VITT.
We compared the modified Rankin scale13 at discharge 
for patients with VITT compared with the non-VITT 
group (figure 3A) and the ISCVT cohort (figure 3B). The 
primary outcome, death or dependency on others for care 
(modified Rankin score 3–6), was significantly more 
common in patients with VITT-associated cerebral venous 
thrombosis (33 [47%] of 70 patients) than in patients 
without VITT (four [16%] of 25 patients; p=0·0061). More 
patients died during admission in the VITT-associated 
cerebral venous thrombosis group (20 [29%] of 70 patients) 
than in the non-VITT group (one [4%] of 25 patients; 
p=0·011). Low Glasgow Coma Scale15 on admission and 
cerebral haemorrhage were the strongest predictors of 




p value (VITT vs 
ISCVT)
Age, years 47 (32–55) 57 (41–62) 0·0045 37 0·0001
Sex 0·31 0·0007
Female 39 (56%) 11 (44%) 465 (75%)
Male 31 (44%) 14 (56%) ·· 159 (25%)
Ethnicity 
White 61 (87%) 21 (84%) 0·74 550/621 (89%) 0·72
Asian 7 (10%) 2 (8%) 1·00 21/621 (3%) 0·017
Black 0 1 (4%) 0·26 31/621 (5%) 0·063
Other or mixed 2 (3%) 1 (4%) 1·00 19/621 (3%) 1·00
Vaccine details
Proportion given AstraZeneca vaccine 70 (100%) 21 (84%) 0·0040 ·· ··
Time from vaccine to cerebral venous 
thrombosis, days
9 (7–12) 11 (6–21) 0·10 ·· ··
Venous risk factors
Patients with no venous risk factors 46 (66%) 11 (44%) 0·057 ·· ··
Patients with no ISCVT risk factors 61 (87%) 20 (80%) 0·51 78 (13%) <0·0001
Fibrinogen, g/L 2·0 (1·3–2·8)* 3·3 (2·9–4·1)† 0·0001 ·· ··
Prothrombin time, s 13·0 (11·9–14·8)‡ 11·5 (10·8–12·6)§ 0·0005 ·· ··
Activated partial thrombloplastin time, s 28·8 (25·1–34·8)¶ 26·9 (24·4–32·7)|| 0·030 ·· ··
Anti-platelet factor 4 antibodies
Positive on ELISA 56/58 (97%) 2/16 (13%) <0·0001 ·· ··
Positive on Acustar HIT-IgG assay 3/13 (23%) 0 0·52 ·· ··
Data are median (IQR), n (%), or n/N (%). Blood results were the closest available to the admission date. Normal ranges are typically fibrinogen 1·9–4·3 g/L, prothrombin time 
10–13 s, and activated partial thromboplastin time 23–30 s. VITT=vaccine-induced immune thrombotic thrombocytopenia. ISCVT=International Study on Cerebral Venous 
Vein and Dural Sinus Thrombosis. *n=59. †n=15. ‡n=69. §n=24. ¶n=67. ||n=24.
Table 1: Demographics, vaccine details, and blood results on admission in patients with VITT-associated cerebral venous thrombosis and those with 
non-VITT cerebral venous thrombosis
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death or dependency, as expected in patients with cerebral 
venous thrombosis (appendix p 6).12
The proportion of patients with VITT who had died or 
were dependent on others for their care at the end of 
admission was significantly lower in those given 
non-heparin parenteral anticoagulation (18 [36%] of 
50 patients) compared with those who were not (15 [75%] 
of 20 patients; p=0·0031), in those who were given a 
direct oral anticoagulant (four [18%] of 22 patients) 
compared with those who were not (29 [60%] of 
48 patients; p=0·0016), and in those who were given 
intravenous immunoglobulin (22 [40%] of 55 patients) 
compared with those who were not (11 [73%] of 
15 patients; p=0·022; table 2).
Among patients treated with parenteral anticoagulants, 
52 were given just one of the two options of heparin (low-
molecular-weight or unfractionated) or a non-heparin 
parenteral alternative (argatroban or fondaparinux). This 
choice appears to have been determined mainly by the 
treatment date rather than patient characteristics—
among patients with VITT, up to March 12, 2021, heparins 
were used, between March 13 and March 18, 2021, there 
was a mixture of heparin and non-heparin parenteral 
anticoagulants, and from March 19, 2021, onwards only 
non-heparin intravenous agents were used (except for 
one patient who was given unfractionated heparin briefly 
Figure 3: Comparison of disability on discharge
(A) Comparison of the outcomes from cerebral venous thrombosis in patients 
with VITT versus patients without VITT. (B) Comparison between VITT-associated 
cerebral venous thrombosis and historical data from the International Study on 
Cerebral Vein and Dural Sinus Thrombosis cohort. Each horizontal bar represents 
the percentage of patients in each modified Rankin scale category, which varies 
from 0 (no symptoms) through to 5 (severe disability). 6 represents death during 
this hospital admission. Diagonal lines and p values show comparisons of death 
and dependency (modified Rankin score 3–6) or death (modified Rankin score 6). 














Proportion in each modified Rankin score category (%)
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Any anticoagulation ·· ·· 0·0047
Yes 60 24 (40%) ··




Yes 16 8 (50%) ··




Yes 50 18 (36%) ··
No 20 15 (75%) ··
Direct oral anticoagulant ·· ·· 0·0016
Yes 22 4 (18%) ··
No 48 29 (60%) ··
Corticosteroid ·· ·· 0·27
Yes 51 22 (43%) ··
No 19 11 (58%) ··
Anticonvulsant ·· ·· 0·71
Yes 26 13 (50%) ··
No 44 24 (55%) ··
Fibrinogen replacement ·· ·· 1·00
Yes 15 7 (47%) ··




Yes 55 22 (40%) ··
No 15 11 (73%) ··
Plasma exchange ·· ·· 0·78
Yes 16 7 (44%) ··
No 54 26 (48%) ··
Platelet transfusion ·· ·· <0·0001
Yes 25 21 (84%) ··
No 45 12 (27%) ··
Invasive
Endovascular management ·· ·· 0·73
Yes 9 5 (56%) ··




Yes 13 13 (100%) ··




Yes 13 13 (100%) ··
No 57 20 (35%) ··
Data are n or n (%). p values are for χ² tests comparing the proportion of patients 
who died or were dependent on others for help with their activities of daily living 
(modified Rankin score 3–6) at the end of their admission in patients treated 
compared with those not treated.
Table 2: Outcomes in patients with cerebral venous sinus thrombosis 
associated with vaccine-induced immune thrombotic thrombocytopenia, 
by treatment modality
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before being switched to argatroban later on the same 
day). Six (67%) of nine patients with VITT-associated 
cerebral venous thrombosis who received some form of 
heparin as their only parenteral anticoagulant had died or 
were dependent on others for their care at the end of 
their hospital admission, whereas 16 (37%) of 43 patients 
given a non-heparin alternative as their only parenteral 
anticoagulant had this poor outcome, although this 
difference was not significant (p=0·14).
Discussion 
To our knowledge, our study provides the most detailed 
information reported to date on the clinical and radio-
logical characteristics of VITT-associated cerebral 
venous thrombosis. The age distribution of our patient 
population was skewed towards older ages because of 
the UK policy of vaccinating older patients first, 
but patients with VITT-associated cerebral venous 
thrombosis were younger than those without VITT. 
Other key findings were that, compared with non-VITT 
patients, those with VITT-associated cerebral venous 
thrombosis had more extensive venous thrombosis and 
higher rates of multiple infarcts, multiple intra cerebral 
haemorrhages, and extracranial thrombosis. VITT was 
associated with significantly more death or dependency 
at the end of hospital admission, but both the use 
of non-heparin anticoagulants and of intravenous 
immunoglobulin were associated with an improved 
outcome. As these treatments become better established, 
the outcomes after VITT-associated cerebral venous 
thrombosis might improve.
The ratio of patients with VITT to patients without 
VITT was 2·8:1, as expected from the estimated 
incidence of VITT-associated cerebral venous thrombosis 
in individuals receiving a first dose of the ChAdOx2 
vaccine (12·3 per million16) and the expected background 
incidence of cerebral venous thrombosis in the same 
subpopulation during the 4-month study period (4·4 per 
million17), suggesting that cerebral venous thrombosis 
was probably unrelated to vaccination in most or all of 
our non-VITT cases and that there was no significant 
bias towards reporting of VITT cases.
A normal platelet count (conventionally ≥150 × 10⁹ per L) 
is regarded as ruling out VITT in existing peer-reviewed 
published guidelines,18,19 but adopting a platelet count 
threshold of less than 150 × 10⁹ per L as a criterion for 
VITT-associated cerebral venous thrombosis in the 
present study could have been a weakness. First, defining 
thrombocytopenia as a fall to less than 50% of a known 
baseline platelet count is recommended in the analogous 
condition of heparin-induced thrombocytopenia.20 Second, 
patient B (appendix p 3), who was excluded from our 
VITT group because her platelet count did not fall 
below 150 × 10⁹ per L, was treated as having VITT because 
of positive anti-PF4 antibodies and very high D-dimer of 
4985 μg/L. Although we regard thrombocytopenia as 
the hallmark for VITT, adopting a hard threshold of 
150 × 10⁹ per L for defining thrombocytopenia risks 
excluding patients who have good evidence of VITT.
Additionally, making D-dimer greater than 2000 μg/L 
an absolute requirement for diagnosis of VITT-associated 
cerebral venous thrombosis might have been suboptimal. 
Patient C (appendix p 3) had cerebral venous sinus 
thrombosis, a platelet count of 110 × 10⁹ per L, and 
positive anti-PF4 antibodies, which is strong evidence for 
VITT, but even after repeated testing her D-dimer was 
never higher than 410 μg/L. Patient D (appendix p 3) had 
a lowest platelet count of 37 × 10⁹ per L and in addition to 
her cerebral venous sinus thrombosis had evidence of 
hepatic vein thrombosis, suspicious for VITT even 
though her anti-PF4 antibody was negative, yet the 
highest D-dimer was only 822 μg/L. Neither patient 
met the criteria for VITT-associated cerebral venous 
thrombosis used in this study, yet both were judged to 
have VITT by their treating clinicians.
Aside from the lowest platelet count and highest 
D-dimer that were used to make the diagnosis of VITT-
associated cerebral venous thrombosis, three other 
features showed a significant association with the diag-
nosis: anti-PF4 antibodies, fibrinogen, and extracranial 
venous thromboses. The specificity of anti-PF4 antibodies 
was probably underestimated in our study, as the only 
two patients who were positive for the antibody but 
were classified as non-VITT using current criteria 
were patients B and C (appendix p 3)—ie, patients with 
probable VITT who were most likely misclassified. 
However, patients E and F (appendix p 3) had evidence 
for VITT but both were negative for anti-PF4 antibodies 
on two different ELISA assays, suggesting that a negative 
ELISA result should not be used to define VITT as 
unlikely19 or to cease further investigation,18 as is recom-
mended in existing guidelines.18,19
These observations lead us to propose a new set of 
diagnostic criteria for VITT-associated cerebral venous 
thrombosis (panel). A diagnosis of possible VITT-
associated cerebral venous thrombosis will alert 
clinicians to an urgent need for further investigation for 
this condition and they are likely to avoid the use of 
heparins or platelet transfusions if possible. A diagnosis 
of probable VITT constitutes sufficient evidence to offer 
a patient full treatment for this condition, including 
intravenous immunoglobulin or plasma exchange. A 
definite diagnosis will be useful for defining a population 
for future research studies on this condition. According 
to these criteria it is possible to make a diagnosis of 
probable VITT in patients with a normal platelet count 
(≥150 × 10⁹ per L), a normal D-dimer, or a negative 
anti-PF4 antibody test, provided other evidence strongly 
supports the diagnosis.
In patients with cerebral venous thrombosis following 
COVID-19 vaccination, anti-PF4 testing should not be 
reserved for patients with admission platelet counts 
below 150 × 10⁹ per L. This strategy would risk missing 
patients with VITT. A patient with a low-normal platelet 
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count may still have anti-PF4 antibodies, as was the case 
for patient B (appendix pp 3–4), and a diagnosis of VITT 
should still be considered while further diagnostic tests 
are undertaken, including further full blood counts.
Clinicians should be aware that patients with VITT-
associated cerebral venous thrombosis are more likely 
to have extracranial thrombosis than other patients with 
cerebral venous thrombosis. Some patients, such as 
patient A (figure 1; appendix p 3), might be dysphasic 
and have difficulty reporting their symptoms.
Anticoagulation and treatment with intravenous 
immunoglobulin were associated with a lower probability 
of death or dependency at the end of hospital admission, 
but this finding is difficult to interpret, as the most unwell 
patients might have died before these treatments could 
be offered, biasing the results. Similarly, the association 
between decompressive hemicraniectomy and poor 
outcome probably reflects selection of patients with the 
most severe cerebral venous thrombosis for this invasive 
procedure. However, the mortality rate of 54% after 
decompressive hemicraniectomy for VITT-associated 
cerebral venous thrombosis is high compared with a 
historical mortality of 16% after this procedure in cerebral 
venous thrombosis.21
The relationship between platelet transfusion and 
poor outcome in VITT-associated cerebral venous 
thrombosis appears to support concerns about the safety 
of this treatment,4 but the findings are difficult to interpret; 
in 12 (48%) of 25 patients offered this treatment, the 
indication was to support decompressive hemicraniectomy, 
which was only offered to patients with severe cerebral 
venous thrombosis.
We present the largest and most detailed study of 
VITT-associated cerebral venous thrombosis to date, with 
a well-matched control group consisting of patients 
presenting to UK hospitals with cerebral venous 
thrombosis after vaccination against COVID-19 but 
without evidence of VITT. However, our study has some 
limitations. The number of patients in each group in our 
study was small, because of the rarity of these conditions. 
The study was underpowered for some of the comparisons 
made between the VITT and non-VITT groups. Although 
our study will generate important hypotheses for 
future research, we cannot draw inferences about other 
populations of patients with cerebral venous thrombosis 
after COVID-19 vaccination. Comparison of our patients 
with the much larger historical ISCVT cohort12 might 
have been confounded by the higher age of our patients, 
attributable to COVID-19 vaccination policy in the UK, 
rather than to VITT. The median interval between 
vaccination and symptom onset could be an under-
estimate; in some cases in which the first symptom of 
cerebral venous thrombosis was reported as headache, 
this symptom might initially have been caused by 
mechanisms other than cerebral venous thrombosis, and 
also patients with a shorter interval might have been 
preferentially reported. We were dependent on local 
radiology reports for interpretation of scans, and on 
routine clinical obser vations, laboratory tests, and 
radiology, which might have led to indication bias. For 
example, we found only one patient with anti-PF4 
antibodies but normal platelets (patient B; appendix p 3), 
but nine (45%) of 20 patients with normal platelets were 
not checked for anti-PF4 antibodies, so other cases with 
this combination might have been missed. We were 
unable to draw firm conclusions about treatments for 
VITT-associated cerebral venous thrombosis because we 
could not control for differences in the baseline 
characteristics between patients offered or not offered 
those treatments.
In conclusion, we have described the clinical features 
of VITT-associated cerebral venous thrombosis in detail, 
allowing us to propose diagnostic criteria for this 
condition. We recommend that all patients presenting 
with cerebral venous thrombosis within 28 days of 
COVID-19 vaccination should be checked for anti-PF4 
antibodies, whatever their platelet count, until there are 
sufficient data to set an upper limit on the platelet count 
with which VITT-associated cerebral venous thrombosis 
might occur. We have shown that VITT-associated 
cerebral venous thrombosis has poorer outcomes than 
other forms of cerebral venous thrombosis and our 
data suggest that non-heparin anticoagulants and 
immunoglobulin might improve outcomes. However, 
VITT appears to be a very rare side-effect of vaccination 
with the ChAdOx1 (Oxford–AstraZeneca) vaccine, the 
risk of which is likely to be greatly outweighed by the 
benefit of vaccination against COVID-19 for most 
people.22
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